Determination of immune parameters related to SARS- CoV-2 vaccinations

Date

2024-12-24

Author

Şanlı, Hatice Asena

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

88
views

22
downloads

Cite This

Virus-like particles (VLP) represent a highly effective vaccine platform with proven effective immunogenicity profiles. Their particulate nature enables display of antigens as repetitive units capable of cross-linking B cell receptors and hence trigger potent antigen specific humoral immunity. Herein, we aimed to study the immunogenicity of a VLP based SARS-CoV-2 vaccine encoding the 4 structural proteins of the virus. Specifically, our objectives were to i) determine the effective dose (ED50) of the VLP vaccine, ii) optimize the doses of CpG ODN and alum adjuvants to induce robust humoral and cellular responses, (iii) analyze age-dependent immune responses to SARS-CoV-2 VLP vaccination, (iv) compare the effectiveness of the inactivated virus and the VLP vaccine platforms and assess their utility for prime-boost strategies, and (v) assess potential sex-based differences in immuno-protective responses. Our results helped establish the dose-response relationship of the VLP vaccine and the adjuvants for optimal immunogenicity, revealed age- and sex- dependent differences in generated immune responses and demonstrated that the VLP platform elicited higher anti-RBD and anti-S IgG titers than the inactivated virus vaccine.

Subject Keywords

SARS-CoV-2, Covid-19, VLP, Virus like particle

URI

https://hdl.handle.net/11511/113058

Collections

Graduate School of Natural and Applied Sciences, Thesis